Drug intelligence / Profile preview

STM-04

Development stage: Preclinical
Lead developer: Secretome Therapeutics
Modality: Recombinant Proteins and Enzymes, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

STM-04 is a preclinical-stage secretome-based therapeutic candidate developed by Secretome Therapeutics for the treatment of Dilated Cardiomyopathy (DCM). The drug is produced using the company's proprietary Secretome Optimization and Production (SOP) platform, which generates a complex mixture of bioactive factors—including proteins, cytokines, and extracellular vesicles (exosomes)—secreted by neonatal mesenchymal stem cells (MSCs). STM-04 is designed to leverage the regenerative and anti-inflammatory properties of these secreted factors to repair damaged cardiac tissue and improve heart function in patients with DCM.

Beyond the preview

Go deeper on STM-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STM-04.

Explore the full profile